Rate My Professor Charles Sentman

Sentman's research centers on innate immunity, NK cells, CD8 T cells, and their regulation of adaptive immunity against cancer and infection. Since 2003, his laboratory has pioneered chimeric antigen receptor (CAR) therapies, developing NKG2D-based CARs targeting tumors expressing ligands like those on ovarian cancer, lymphoma, myeloma, breast cancer, melanoma, and osteosarcoma. Additional efforts include bi-specific T cell engagers against tumor ligands such as MICA, B7H6, and ULBPs, and CAR Tregs for neurodegenerative diseases including Alzheimer's, ALS, and Parkinson's. Key publications encompass 'NKG2D CAR T cell therapy inhibits the growth of antigen heterogeneous tumors' (2013), 'Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma' (2019), 'Human CAR Tregs Targeting SOD1 and Expressing BDNF Reduce Inflammation and Delay Disease in G93A hSOD1-NSG Mice' (2025), and '5xFAD-NSG mice: a preclinical Alzheimer model for human cell therapy studies' (2026). With over 100 peer-reviewed publications and more than 30 issued US patents, Sentman co-founded Oncyte, acquired by Celyad in 2015, and Black Bear Bio, advancing therapies toward clinical development in collaboration with Celdara Medical and Dartmouth-Hitchcock Medical Center. In 2022, he was named a Fellow of the National Academy of Inventors for his innovations in immune cell engineering.